文献速递艾滋病与性传播感染

喀麦隆接受抗逆转录病毒治疗的青少年中低水平或高水平病毒血症者的HIV耐药流行率

Prevalence of HIV drug resistance among adolescents receiving ART in Cameroon with low- or high-level viraemia.
PubMed 文献 · J Antimicrob Chemother · 2023-01-01

该研究对280名接受抗逆转录病毒治疗至少6个月的10-19岁青少年中低水平病毒血症(200-999拷贝/mL)和病毒学失败(确认VL≥1000拷贝/mL)两组进行基因型耐药检测,发现两组均有高水平耐药,低水平病毒血症组84.6%(22/26)和病毒学失败组75.0%(21/28)携带至少一种HIV耐药突变,作者呼吁修订WHO病毒学失败定义。

要点

  • 低水平病毒血症组84.6%(22/26)和病毒学失败组75.0%(21/28)携带至少一种HIV耐药突变。
  • 两组中NRTI和NNRTI类耐药最常见,PI类未显著受影响,所有受检者预期多替拉韦有活性。
  • 低水平病毒血症组中22.7%(5/22)在多替拉韦联合方案下可能为功能性单药治疗(仅多替拉韦有活性)。

核心结论

  • 1000拷贝/mL阈值并非病毒学成功的指标,作者呼吁修订资源有限国家当前的WHO病毒学失败定义。

研究设计与样本

  • 来自280名接受ART至少6个月的10-19岁青少年队列,对低水平病毒血症(VL 200-999拷贝/mL)和病毒学失败(确认VL≥1000拷贝/mL)两组尝试进行基因型耐药检测,采用in-house方法,并用Stanford HIValg程序识别耐药突变及预测替诺福韦-拉米夫定-多替拉韦联合方案疗效。

主要发现

  • 基因型耐药检测在54/58(93.1%)合格受检者中成功完成,其中病毒学失败组28/31(90.3%),低水平病毒血症组26/27(96.3%)。
  • 低水平病毒血症组84.6%(22/26)和病毒学失败组75.0%(21/28)携带至少一种HIV耐药突变。
  • 两组中NRTI和NNRTI类耐药最常见,PI类未显著受影响,所有受检者预期多替拉韦有活性。
  • 低水平病毒血症组中22.7%(5/22)在新引入的多替拉韦联合方案下可能为功能性单药治疗(仅多替拉韦有活性)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To characterize HIV drug resistance (HIVDR) below and above the WHO threshold of 1000 copies/mL, considered for the definition of HIV ART failure in resource-limited settings. METHODS: From a cohort of 280 adolescents (aged 10-19 years) receiving ART for at least 6 months, genotypic resistance testing (GRT) was attempted for two groups of participants: participants with low-level viraemia [LLV; viral load (VL) 200-999 copies/mL] and those in virological failure (VF; confirmed VL ≥1000 copies/mL) using an in-house method. The Stanford HIValg Program was used to identify relevant HIVDR mutations and predict the efficacy of the newly introduced tenofovir-lamivudine-dolutegravir combination. RESULTS: GRT was successfully performed in 54/58 (93.1%) eligible participants, of which 28/31 (90.3%) were in VF and 26/27 (96.3%) had LLV. A high level of resistance was found both in adolescents with LLV and those in VF, with respectively 84.6% (22/26) and 75.0% (21/28) of participants harbouring at least one HIVDR mutation. NRTIs and NNRTIs were the most affected drug classes in both population groups. In contrast, PIs were not significantly affected and dolutegravir was expected to be active for all participants tested. However, for the newly introduced dolutegravir-based combination, functional monotherapy (dolutegravir only) was potentially possible for 22.7% (5/22) of the participants with LLV. CONCLUSIONS: Our findings show that the 1000 copies/mL threshold is not an indicator of virological success and we call for a revision of the current WHO definition of VF in resource-limited countries.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Djiyou ABD, Penda CI, Madec Y, et al. Prevalence of HIV drug resistance among adolescents receiving ART in Cameroon with low- or high-level viraemia. J Antimicrob Chemother. 2023. PMID: 37921335. doi:10.1093/jac/dkad334

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。